Table 2.
Prevalence of serum autoantibodies in patients and controls from Crete, Greece.
| HCV positive patients | Healthy blood donors | |||||
| Autoantibody | (142) | (60) | ||||
| Titres | Titres | |||||
| n. | % | n. | % | |||
| median | median | |||||
| ANA | 72 | 50.7* | 1:80 | 4 | 6.7* | 1:80 |
| ASMA | 33 | 23.2* | 1:160 | 1 | 1.7* | 1:40 |
| anti-gastric parietal cells | 20 | 14.1* | 1:40 | 0 | -* | - |
| anti-IMF | 13 | 9.1* | 1:40 | 0 | -* | - |
| anti-double stranded DNA | 4 | 2.8 | 1:120 | 0 | - | - |
| anti-spindle apparatus | 4 | 2.8 | 1:480 | 0 | - | - |
| anti-reticulin | 3 | 2.1 | 1:160 | 0 | - | - |
| anti-MF | 2 | 1.4 | 1:160 | 0 | - | - |
| anti-Golgi appartus | 1 | 0.7 | 1:160 | 0 | - | - |
| AMA | 1 | 0.7 | 1:640 | 0 | - | - |
| LKM1 | 1 | 0.7 | 1:40 | 0 | - | - |
* p < 0.01